FAKTOR OPTIONSSCHEIN - GENMAB | Market Closed - Deutsche Boerse AG 15:21:03 17/05/2024 BST | ||
| 7.53 EUR | +0.13% |
|
| 3 months | -3.34% | ||
| 6 months | -37.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 7.53 | +0.13% |
| 16/05/24 | 7.52 | -3.59% |
| 15/05/24 | 7.8 | +4.14% |
| 14/05/24 | 7.49 | +6.39% |
| 13/05/24 | 7.04 | -4.99% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 03:21 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PN3GEN |
| ISIN | DE000PN3GEN1 |
| Date issued | 17/11/2021 |
| Strike | 2,026 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 58.56 € |
|---|---|
| Lowest since issue | 6.2 € |
| Spread | 0.03 € |
| Spread % | 0.39% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,041
DKK
Average target price
2,470
DKK
Spread / Average Target
+21.01%
- Stock Market
- Certificates
- Certificat
